{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:14:19Z","timestamp":1756898059845,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Abiraterone is a medication frequently used for metastatic castrate-resistant prostate cancer. We report a case of non-sustained episodes of TdP associated with severe hypokalemia due to androgen-deprivation therapy. Few case presentations describe this association; the novelty lies in the potentially lethal cardiovascular events among cancer patients receiving hormonal therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 70-year-old male presented with recurrent syncope without prodrome. ECG revealed frequent ventricular ectopy, non-sustained episodes of TdP, and severe hypomagnesemia and hypokalemia. During potassium and magnesium infusion for repletion, the patient underwent temporary transvenous atrial pacing. As part of the work-up, coronary angiography revealed a mild coronary artery disease, and transthoracic echocardiogram showed a moderately depressed ejection fraction. After electrolyte disturbances were corrected, the QT interval normalized, and transvenous pacing was no longer necessary. Abiraterone was discontinued during the admission, and the patient returned to baseline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Cancer treatment is complex and requires a multidisciplinary approach. We presented a case of non-sustained TdP associated with androgen-deprivation therapy in an elderly patient with mild coronary artery disease and moderately reduced ejection fraction. Close follow-up and increased awareness are required in patients with hormonal treatment, especially in the setting of other cardiovascular risk factors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-021-01945-3","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T12:06:50Z","timestamp":1615550810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Syncope due to non-sustained episodes of Torsade de Pointes associated to androgen-deprivation therapy use: a case presentation"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8945-3625","authenticated-orcid":false,"given":"Ximena","family":"Morales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Garnica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Isaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Isaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Dur\u00e1n-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"issue":"1","key":"1945_CR1","first-page":"57","volume":"20","author":"J Cassinello","year":"2018","unstructured":"Cassinello J, Arranz J\u00c1, Piulats JM, S\u00e1nchez A, P\u00e9rez-Valderrama B, Mellado B, et al. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2018;20(1):57\u201368.","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"issue":"18","key":"1945_CR2","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s40265-013-0150-z","volume":"73","author":"SM Hoy","year":"2013","unstructured":"Hoy SM. Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer. Drugs. 2013;73(18):2077\u201391.","journal-title":"Drugs"},{"issue":"7","key":"1945_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.4155\/cli.12.55","volume":"2","author":"D Schrijvers","year":"2012","unstructured":"Schrijvers D. Abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer: review of clinical data. Clin Investig. 2012;2(7):707\u201313.","journal-title":"Clin Investig"},{"key":"1945_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/DDDT.S15850","volume":"6","author":"Y Rehman","year":"2012","unstructured":"Rehman Y, Rehman Y. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther. 2012;6:13\u20138.","journal-title":"Drug Des Devel Ther."},{"issue":"4","key":"1945_CR5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352\u201360.","journal-title":"N Engl J Med"},{"key":"1945_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.117.005443","author":"V Buza","year":"2017","unstructured":"Buza V, Rajagopalan B, Curtis AB. Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies. Circ Arrhythm Electrophysiol. 2017. https:\/\/doi.org\/10.1161\/CIRCEP.117.005443.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1945_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007724","author":"A Porta-S\u00e1nchez","year":"2017","unstructured":"Porta-S\u00e1nchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/JAHA.117.007724.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1945_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40885-019-0116-x","volume":"25","author":"X Zhu","year":"2019","unstructured":"Zhu X, Wu S. Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis. Clin Hypertens. 2019;25(1):12.","journal-title":"Clin Hypertens"},{"issue":"3","key":"1945_CR9","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","volume":"16","author":"R Iacovelli","year":"2018","unstructured":"Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer. 2018;16(3):e645\u201353.","journal-title":"Clin Genitourin Cancer"},{"key":"1945_CR10","unstructured":"Center for Drug Evaluation and Research. October - December 2018 | Potential Signals of Serious Risks\/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS). FDA [Internet]. 2019 Dec 20 [cited 2020 Jun 13]; Available from: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/october-december-2018-potential-signals-serious-risksnew-safety-information-identified-fda-adverse"},{"issue":"1445","key":"1945_CR11","first-page":"124","volume":"129","author":"A Khan","year":"2016","unstructured":"Khan A, Kneale B. Life threatening torsades de pointes due to abiraterone-induced hypokaelemia in a patient with metastatic prostate cancer. N Z Med J. 2016;129(1445):124\u20137.","journal-title":"N Z Med J"},{"issue":"1","key":"1945_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/1060028014555362","volume":"49","author":"F Rodieux","year":"2015","unstructured":"Rodieux F, Nieto N, Sunthorn H, John G, Escher M. Abiraterone acetate-induced life-threatening Torsade de Pointes. Ann Pharmacother. 2015;49(1):152\u20133.","journal-title":"Ann Pharmacother"},{"key":"1945_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pharmthera.2016.07.005","volume":"167","author":"J-E Salem","year":"2016","unstructured":"Salem J-E, Alexandre J, Bachelot A, Funck-Brentano C. Influence of steroid hormones on ventricular repolarization. Pharmacol Ther. 2016;167:38\u201347.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"1945_CR14","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1161\/ATVBAHA.119.313046","volume":"40","author":"J-R Hu","year":"2020","unstructured":"Hu J-R, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. Arterioscler Thromb Vasc Biol. 2020;40(3):e55-64.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1945_CR15","doi-asserted-by":"crossref","unstructured":"Lazzerini PE, Bertolozzi I, Acampa M, Cantara S, Castagna MG, Pieragnoli L, et al. Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes. Front Pharmacol [Internet]. 2020 May 13 [cited 2020 Dec 25];11. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7239032\/","DOI":"10.3389\/fphar.2020.00684"},{"issue":"1","key":"1945_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.118.034282","volume":"138","author":"J-E Salem","year":"2018","unstructured":"Salem J-E, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, et al. Hypogonadism as a reversible cause of Torsade de Pointes in men. Circulation. 2018;138(1):110\u20133.","journal-title":"Circulation"},{"issue":"5","key":"1945_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/js.2018-00039","volume":"2","author":"T Gagliano-Juc\u00e1","year":"2018","unstructured":"Gagliano-Juc\u00e1 T, Travison TG, Kantoff PW, Nguyen PL, Taplin M-E, Kibel AS, et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer. J Endocr Soc. 2018;2(5):485\u201396.","journal-title":"J Endocr Soc"},{"issue":"2","key":"1945_CR18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.eururo.2019.07.031","volume":"77","author":"G Lu-Yao","year":"2020","unstructured":"Lu-Yao G, Nikita N, Keith SW, Nightingale G, Gandhi K, Hegarty SE, et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol. 2020;77(2):158\u201366.","journal-title":"Eur Urol"},{"key":"1945_CR19","doi-asserted-by":"crossref","unstructured":"Lazzerini PE, Capecchi PL, El\u2010Sherif N, Laghi\u2010Pasini F, Boutjdir M. Emerging Arrhythmic Risk of Autoimmune and Inflammatory Cardiac Channelopathies. J Am Heart Assoc Cardiovasc Cerebrovasc Dis [Internet]. 2018 Nov 13 [cited 2020 Dec 25];7(22). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6404431\/","DOI":"10.1161\/JAHA.118.010595"},{"issue":"22","key":"1945_CR20","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1136\/heartjnl-2016-311079","volume":"103","author":"PE Lazzerini","year":"2017","unstructured":"Lazzerini PE, Laghi-Pasini F, Bertolozzi I, Morozzi G, Lorenzini S, Simpatico A, et al. Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes. Heart. 2017;103(22):1821\u20139.","journal-title":"Heart"},{"issue":"2","key":"1945_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00280-012-1916-9","volume":"70","author":"AW Tolcher","year":"2012","unstructured":"Tolcher AW, Chi KN, Shore ND, Pili R, Molina A, Acharya M, et al. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2012;70(2):305\u201313.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"1945_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/1758834016656493","volume":"8","author":"E Verzoni","year":"2016","unstructured":"Verzoni E, Grassi P, Ratta R, Niger M, De Braud F, Valdagni R, et al. Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. Ther Adv Med Oncol. 2016;8(5):323\u201330.","journal-title":"Ther Adv Med Oncol"},{"issue":"48","key":"1945_CR23","doi-asserted-by":"publisher","first-page":"84572","DOI":"10.18632\/oncotarget.20028","volume":"8","author":"RB Moreira","year":"2017","unstructured":"Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco GD, Maluf FC, et al. Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget. 2017;8(48):84572\u20138.","journal-title":"Oncotarget"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-01945-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-021-01945-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-01945-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T12:08:09Z","timestamp":1615550889000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-01945-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1945"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-01945-3","relation":{},"ISSN":["1471-2261"],"issn-type":[{"type":"electronic","value":"1471-2261"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"8 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The patient gave written consent for clinical and personal details along with any identifying images to be published in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"136"}}